Form 4: ALX Oncology CEO Jason Lettmann Granted Stock Options

ALX Oncology's CEO, Jason Lettmann, was granted 200,000 stock options on December 2, 2024, which vest over 30 months starting January 2, 2025.

Summary

• Jason Lettmann, CEO of ALX Oncology Holdings Inc., was granted 200,000 employee stock options on December 2, 2024.
• The exercise price of these options is $1.66 per share.
• The options vest in 30 equal monthly installments beginning on January 2, 2025.
• The options expire on December 1, 2031.
• A power of attorney was also executed on December 3, 2024, authorizing Chris Byrd and Shelly Pinto to file necessary SEC forms on behalf of Mr. Lettmann.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative sentiment.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

The stock options will vest over the next 30 months, incentivizing the CEO to focus on long-term value creation.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the biotech industry.
• The vesting schedule of 30 months is typical for such grants, aligning with long-term performance goals.
• The exercise price of $1.66 is a common practice, often set at or near the market price at the time of the grant.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CEO to increase shareholder value.
• The CEO is incentivized to improve the company's performance to benefit from the stock options.

Next Steps

• The stock options will vest monthly over the next 30 months.
• The power of attorney will be used to file future SEC forms related to the CEO's transactions.

Key Dates

Keywords

stock options, executive compensation, SEC Form 4, ALX Oncology, Jason Lettmann, insider trading, equity, vesting